Chimeric antigen receptor T-cell therapy: Prospective observational study of unplanned emergency department presentations.
chimeric antigen receptor T-cell therapy
cytokine release syndrome
haematology
immune effector cell-associated neurotoxicity syndrome
unplanned presentation
Journal
Emergency medicine Australasia : EMA
ISSN: 1742-6723
Titre abrégé: Emerg Med Australas
Pays: Australia
ID NLM: 101199824
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
22
07
2023
received:
16
01
2023
accepted:
09
08
2023
pubmed:
6
9
2023
medline:
6
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
Chimeric antigen receptor T-cell (CAR-T) therapy is an emerging treatment for refractory hematologic malignancy. Unplanned ED presentations following CAR-T present the increasing need for an integrated model of care that allows for the early recognition of its specific complications. This is a prospective observational study at a tertiary centre. CAR-T patients (n = 17) were universally enrolled into a study registry by treating providers. These patients were flagged by investigators to trigger a pop-up notification CAR-T information warning at ED triage. Medical records were reviewed 90 days for unplanned presentations, complications and patient-oriented outcomes. Patients receiving CAR-T frequently encountered toxicity within 7 days of therapy. This was typically mild and occurred in an inpatient setting. Medical record review revealed five unplanned ED presentations (that were recognised as post CAR-T) and not directly attributable to specific toxicities. If CAR-T therapy is to be used more widely especially in an outpatient model of care, a standardised ED model of care for recognition of specific complications is needed.
Identifiants
pubmed: 37669879
doi: 10.1111/1742-6723.14300
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1034-1037Informations de copyright
© 2023 Australasian College for Emergency Medicine.
Références
Keng MK, Thallner EA, Elson P et al. Reducing time to antibiotic administration for febrile neutropenia in the emergency department. J. Oncol. Pract. 2015; 11: 450-455.
Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol. Oncol. 2019; 37: 95-100.
Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther. Clin. Risk Manag. 2019; 28: 323-335.
Kachalia A, Gandhi TK, Puopolo AL et al. Missed and delayed diagnoses in the emergency department: a study of closed malpractice claims from 4 liability insurers. Ann. Emerg. Med. 2007; 49: 196-205.
Pennisi M, Jain T, Santomasso BD et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020; 4: 676-686.